AlphaFold predicted structure
MBOAT7 · Q96N66

Mean pLDDT
92.0/ 100
Very high
472 residues
Confidence breakdown
- Very high(≥ 90)86%
- Confident(70–90)9%
- Low(50–70)2%
- Very low(< 50)4%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
membrane bound acylglycerophosphatidylinositol O-acyltransferase MBOAT7
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
DDG2P
BIALLELIC, autosomal or pseudoautosomalEarly onset or syndromic epilepsy
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalintellectual disability, autosomal recessive 57
hereditary disease
autosomal recessive non-syndromic intellectual disability
complex neurodevelopmental disorder
neurodegenerative disease
Neurodevelopmental abnormality
Intellectual disability
metabolic dysfunction-associated steatotic liver disease
metabolic dysfunction-associated steatohepatitis
nonpapillary renal cell carcinoma
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Membrane-bound acylglycerophosphatidylinositol O-acyltransferase MBOAT7
Acyltransferase which catalyzes the transfer of an acyl group from an acyl-CoA to a lysophosphatidylinositol (1-acylglycerophosphatidylinositol or LPI) leading to the production of a phosphatidylinositol (1,2-diacyl-sn-glycero-3-phosphoinositol or PI) and participates in the reacylation step of the phospholipid remodeling pathway also known as the Lands cycle (PubMed:18094042, PubMed:18772128). Prefers arachidonoyl-CoA as the acyl donor, thus contributing to the regulation of free levels arachidonic acid in cell (PubMed:18094042, PubMed:18772128). In liver, participates in the regulation of triglyceride metabolism through the phosphatidylinositol acyl-chain remodeling regulation (PubMed:32253259)
MBOAT7 · Q96N66

Mean pLDDT
92.0/ 100
Very high
472 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0